Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis

BACKGROUND: Liraglutide is a novel, long-acting glucagon-like peptide-1 (GLP-1) analogue used to treat type 2 diabetes mellitus. However, the cardiovascular safety and benefits of liraglutide treatment on type 2 diabetes patients remain in debate. In this study, we aimed to examine the overall cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Chun-Mei, Wan, Teng-Fei, Wang, Yue, Yang, Qing-Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867782/
https://www.ncbi.nlm.nih.gov/pubmed/31725627
http://dx.doi.org/10.1097/MD.0000000000017860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867782/
https://www.ncbi.nlm.nih.gov/pubmed/31725627
http://dx.doi.org/10.1097/MD.0000000000017860

Ejemplares similares